Hyderabad firm develops AI-powered phyto-medicines

Metro India News | Hyderabad

Hyderabad-based biotechnology company Acubiosys Private Limited has developed innovative AI- and nanotechnology-enabled herbal medicines for the treatment of psoriasis and chronic diabetic wounds, offering an advanced approach to managing difficult skin and wound conditions.

The company, incubated at the Technology Incubator of the BRIC-Centre for DNA Fingerprinting and Diagnostics (BRIC-CDFD), has launched two patented formulations developed using artificial intelligence and nanotechnology. BOCUGL is a topical medicine for psoriasis, atopic dermatitis and melasma, while AZBECO has been formulated for chronic wounds and diabetic foot ulcers.

Both products are manufactured in India in accordance with AYUSH regulations and Good Manufacturing Practices (GMP), reflecting the company's focus on quality and indigenous healthcare innovation.

Acubiosys has also filed patent applications in India, China and the United States as it expands its global intellectual property portfolio. The company is further enhancing its AI-driven drug discovery platform to develop next-generation phytopharmaceuticals for autoimmune and infectious diseases.

Founder and CEO Dr. Srinivas Maddi said the company's goal is to combine artificial intelligence, nanotechnology and life sciences to develop affordable, evidence-based therapies while strengthening India's biotechnology innovation ecosystem.